Formulation and In-vitro Evaluation of Bilayer Tablet of Olmesartan Medoxomil for Biphasic Drug Release

Objective: The current study aimed to optimize the bioavailability and absorption of olmesartan in the lower gastrointestinal tract by creating a bilayer tablet for biphasic drug release. Methods: Microcrystalline cellulose was combined and direct compression the requirement for an early response to address an undesirable defect or condition. In the current instance, 5 mg of olmesartan must be released immediately, and the remaining 10 mg of olmesartan must be released gradually to maintain the therapeutic concentration. In order to adjust the release pattern of the olmesartan sustained release tablet in accordance with the needs of therapy and IP guidelines. Result: The best cumulative drug release was demonstrated by formulation. All formulations for immediate release support the first-order kinetics. As a result, all three formulations were chosen for additional research. Dissolution rate for long-term release Cumulative drug release from the SR1 to SR3 formulations using HPMC K15M and gum acacia was up to 24 hours. Utilizing HPMC K15M and guar gum, the formulations SR1, SR2, and SR3 demonstrated cumulative drug releases of 72.66, 69.19, and 92.66%, respectively. The best cumulative release of the drug was demonstrated by formulations SR1, SR2, and SR3. Consequently, everyone was chosen for additional research. The cumulative drug release for the IR1-SR1, IR2-SR2, and IR3-SR3 bilayer tablet formulations was 95.24, 90.15, and 91.09%. Up to 12 hours of cumulative drug release from the formulation was observed. As a result, it was determined that IR1-SR1 was the best formulation out of all of them due to its strong correlation between the total cumulative percentage of medication releases and time, which was 95.24% up to 12 hours.